-
公开(公告)号：WO2010072740A3
公开(公告)日：2010-10-21
申请号：PCT/EP2009067706
申请日：2009-12-21
Applicant: ASTRAZENECA AB , EBERLEIN CATHERINE ANNE , FOLTZ IAN , KANG PAUL , KENDREW JANE , ALFRED AVRIL , BARRY SIMON THOMAS
Inventor： EBERLEIN CATHERINE ANNE , FOLTZ IAN , KANG PAUL , KENDREW JANE , ALFRED AVRIL , BARRY SIMON THOMAS
IPC: C07K16/28 , A61K39/395 , A61P35/00
CPC classification number: C07K16/2842 , A61K2039/505 , C07K2317/21 , C07K2317/56 , C07K2317/565 , C07K2317/73 , C07K2317/76 , C07K2317/92
Abstract: The invention relates to targeted binding agents against a5ß1 and uses of such agents. More specifically, the invention relates to fully human monoclonal antibodies directed to a5ß1. The described targeted binding agents are useful in the treatment of diseases associated with the activity and/or overproduction of a5ß1 and as diagnostics.
Abstract translation: 本发明涉及针对α5β1的靶向结合剂和这些试剂的用途。 更具体地说，本发明涉及针对α5β1的完全人单克隆抗体。 所述的靶向结合剂可用于治疗与α5β1的活性和/或过量产生相关的疾病，并作为诊断。
-
Patent Agency Ranking
公开(公告)号：WO2010072741A1
公开(公告)日：2010-07-01
申请号：PCT/EP2009/067707
申请日：2009-12-21
Applicant: ASTRAZENECA AB , BARRY, Simon Thomas , EBERLEIN, Catherine Anne , FOLTZ, Ian , KANG, Paul , KENDREW, Jane , ALFRED, Avril
Inventor： BARRY, Simon Thomas , EBERLEIN, Catherine Anne , FOLTZ, Ian , KANG, Paul , KENDREW, Jane , ALFRED, Avril
IPC: C07K16/28 , A61K39/395 , A61P35/00
CPC classification number: C07K16/2842 , A61K2039/505 , C07K2317/21 , C07K2317/56 , C07K2317/565 , C07K2317/73 , C07K2317/76 , C07K2317/92
Abstract: The invention relates to targeted binding agents against α5β1 and uses of such agents. More specifically, the invention relates to fully human monoclonal antibodies directed to α5β1. The described targeted binding agents are useful in the treatment of diseases associated with the activity and/or overproduction of α5β1 and as diagnostics.
Abstract translation: 本发明涉及针对a5β1的靶向结合剂和这些药剂的用途。 更具体地，本发明涉及针对a5β1的完全人单克隆抗体。 所描述的靶向结合剂可用于治疗与α5β的活性和/或过量产生相关的疾病和作为诊断。
-
公开(公告)号：WO2008112004A3
公开(公告)日：2009-04-02
申请号：PCT/US2007075120
申请日：2007-08-02
Applicant: ASTRAZENECA AB , FOLTZ IAN , RINKENBERGER JULIE , ALFRED AVRIL , BARRY SIMON THOMAS , BEDIAN VAHE
Inventor： FOLTZ IAN , RINKENBERGER JULIE , ALFRED AVRIL , BARRY SIMON THOMAS , BEDIAN VAHE
CPC classification number: C07K16/2839 , A61K2039/505 , C07K2317/21 , C07K2317/56 , C07K2317/565 , C07K2317/567 , C07K2317/76 , C07K2317/92 , C12N5/0686 , C12N2501/998
Abstract: Targeted binding agents, such antibodies directed to the antigen aVß6 and uses of such agents are described. In particular, fully human monoclonal antibodies directed to the antigen aVß6 are disclosed. Nucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions and/or complementarity determining regions (CDR's), specifically from FR1 through FR4 or CDR1 through CDR3 are disclosed. Hybridomas or other cell lines expressing such immunoglobulin molecules and monoclonal antibodies are also disclosed.
Abstract translation: 描述了靶向结合剂，针对抗原aVβ6的这种抗体以及这些药剂的用途。 特别地，公开了针对抗原aVβ6的完全人单克隆抗体。 编码的核苷酸序列和包含重链和轻链免疫球蛋白分子的氨基酸序列，特别是对应于跨越框架区和/或互补决定区（CDR）的连续重链和轻链序列的序列，特别是从FR1至FR4或CDR1至CDR3 被披露。 还公开了表达这种免疫球蛋白分子和单克隆抗体的杂交瘤或其它细胞系。
-
公开(公告)号：WO2008112004A2
公开(公告)日：2008-09-18
申请号：PCT/US2007/075120
申请日：2007-08-02
Applicant: ASTRAZENECA AB , FOLTZ, Ian , RINKENBERGER, Julie , ALFRED, Avril , BARRY, Simon Thomas , BEDIAN, Vahe
Inventor： FOLTZ, Ian , RINKENBERGER, Julie , ALFRED, Avril , BARRY, Simon Thomas , BEDIAN, Vahe
IPC: C07K16/00
CPC classification number: C07K16/2839 , A61K2039/505 , C07K2317/21 , C07K2317/56 , C07K2317/565 , C07K2317/567 , C07K2317/76 , C07K2317/92 , C12N5/0686 , C12N2501/998
Abstract: Targeted binding agents, such antibodies directed to the antigen αVβ6 and uses of such agents are described. In particular, fully human monoclonal antibodies directed to the antigen αVβ6 are disclosed. Nucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions and/or complementarity determining regions (CDR's), specifically from FR1 through FR4 or CDR1 through CDR3 are disclosed. Hybridomas or other cell lines expressing such immunoglobulin molecules and monoclonal antibodies are also disclosed.
Abstract translation: 描述了靶向结合剂，针对抗原aVβ6的这种抗体以及这些药剂的用途。 特别地，公开了针对抗原aVβ6的完全人单克隆抗体。 编码的核苷酸序列和包含重链和轻链免疫球蛋白分子的氨基酸序列，特别是对应于跨越框架区和/或互补决定区（CDR）的连续重链和轻链序列的序列，特别是从FR1至FR4或CDR1至CDR3 被披露。 还公开了表达这种免疫球蛋白分子和单克隆抗体的杂交瘤或其它细胞系。
-
公开(公告)号：WO2010072740A2
公开(公告)日：2010-07-01
申请号：PCT/EP2009/067706
申请日：2009-12-21
Applicant: ASTRAZENECA AB , EBERLEIN, Catherine Anne , FOLTZ, Ian , KANG, Paul , KENDREW, Jane , ALFRED, Avril , BARRY, Simon Thomas
Inventor： EBERLEIN, Catherine Anne , FOLTZ, Ian , KANG, Paul , KENDREW, Jane , ALFRED, Avril , BARRY, Simon Thomas
IPC: C07K16/28 , A61K39/395 , A61P35/00
CPC classification number: C07K16/2842 , A61K2039/505 , C07K2317/21 , C07K2317/56 , C07K2317/565 , C07K2317/73 , C07K2317/76 , C07K2317/92
Abstract: The invention relates to targeted binding agents against α5β1 and uses of such agents. More specifically, the invention relates to fully human monoclonal antibodies directed to α5β1. The described targeted binding agents are useful in the treatment of diseases associated with the activity and/or overproduction of α5β1 and as diagnostics.
Abstract translation: 本发明涉及针对a5β1的靶向结合剂和这些药剂的用途。 更具体地，本发明涉及针对a5β1的完全人单克隆抗体。 所描述的靶向结合剂可用于治疗与α5β的活性和/或过量产生相关的疾病和作为诊断。
-
公开(公告)号：WO2010072741A9
公开(公告)日：2010-07-01
申请号：PCT/EP2009/067707
申请日：2009-12-21
Applicant: ASTRAZENECA AB , BARRY, Simon Thomas , EBERLEIN, Catherine Anne , FOLTZ, Ian , KANG, Paul , KENDREW, Jane , ALFRED, Avril
Inventor： BARRY, Simon Thomas , EBERLEIN, Catherine Anne , FOLTZ, Ian , KANG, Paul , KENDREW, Jane , ALFRED, Avril
IPC: C07K16/28 , A61K39/395 , A61P35/00
Abstract: The invention relates to targeted binding agents against α5β1 and uses of such agents. More specifically, the invention relates to fully human monoclonal antibodies directed to α5β1. The described targeted binding agents are useful in the treatment of diseases associated with the activity and/or overproduction of α5β1 and as diagnostics.
-
-
-
-
-
Search Results
6
records
(took 0.016 seconds)
